February 11, 2021
Article
Response rates in patients with metastatic urothelial carcinoma were boosted when the novel PI3K-y inhibitor eganelisib was added to nivolumab, according to recent research presented during the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.
January 28, 2021
Article
A correlation between the emergence of immune-related adverse events and presence of mutations was identified in patients with non-small lung cancer receiving immunotherapy.
September 21, 2020
Article
Patients with epithelial ovarian cancer treated with weekly dose-dense chemotherapy in the ICON8 clinical trial experienced similar progression-free survival and overall survival as patients treated with the standard-of-care.
May 30, 2020
Article
Another treatment option would be a welcome change for these patients, who tend to have poor prognoses once they run out of treatment options, according to Saad Z. Usmani, MD. After becoming refractory to available therapies, median overall survival is 6-11 months.